The clinical relevance of human papillomavirus negative status in unsatisfactory cervical cytology
- PMID: 36484851
- DOI: 10.1007/s00404-022-06870-0
The clinical relevance of human papillomavirus negative status in unsatisfactory cervical cytology
Abstract
Purpose: The aim of this study was to evaluate the clinical relevance of high-risk human papillomavirus (HR-HPV) negativity at the time of unsatisfactory cervical cytology.
Methods: In this retrospective observational study, records were reviewed for patients who had unsatisfactory cervical cytology with HR-HPV testing performed from January 2015 through September 2019 at a large teaching hospital. Pathology results of follow-up cervical cytology and biopsies were assessed.
Results: Of 1282 patients with unsatisfactory cervical cytology and negative HR-HPV testing, repeat cytology was negative for intraepithelial lesion (NIL) in 952 (75%) patients, unsatisfactory in 273 (22%) patients, and abnormal in 41 (3%) patients. Median follow-up time was 91 days. The concordance of HR-HPV status between initial unsatisfactory cervical cytology and subsequent satisfactory cervical cytology was 96.3% for HR-HPV negative patients and 68.8% for HR-HPV positive patients. Compared to women who were HR-HPV negative, women who were HR-HPV positive on initial unsatisfactory cytology were at higher risk of subsequent cervical intraepithelial neoplasia (CIN) 2 or greater (odds ratio = 4.91, 95% confidence interval: 1.34-18.03 for E6/E7 mRNA positivity alone; odds ratio = 46.13, 95% confidence interval: 13.45-158.01 for HR-HPV genotype 16 or 18/45 positivity).
Conclusion: In the 3 month follow-up of patients with unsatisfactory cervical cytology and negative HR-HPV testing, approximately 3% had abnormal cytology but no cases of HPV related pathology of CIN 2 or greater were found. There was high concordance of negative HR-HPV testing results with those on follow-up satisfactory cervical cytology.
Keywords: Cervical cancer screening; HPV; High-risk papillomavirus; Pap test; Unsatisfactory.
© 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Similar articles
-
High-risk human papillomavirus DNA test results are useful for disease risk stratification in women with unsatisfactory liquid-based cytology pap test results.J Low Genit Tract Dis. 2009 Apr;13(2):79-84. doi: 10.1097/LGT.0b013e31818474fd. J Low Genit Tract Dis. 2009. PMID: 19387127
-
Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.BJOG. 2006 Nov;113(11):1303-7. doi: 10.1111/j.1471-0528.2006.01063.x. Epub 2006 Sep 15. BJOG. 2006. PMID: 16978225
-
Yield and mode of diagnosis of cervical intraepithelial neoplasia 3 or cancer among women with negative cervical cytology and positive high-risk human papillomavirus test results.J Low Genit Tract Dis. 2013 Oct;17(4):430-9. doi: 10.1097/LGT.0b013e318281f182. J Low Genit Tract Dis. 2013. PMID: 23595040
-
Discrepant HPV/cytology cotesting results: Are there differences between cytology-negative versus HPV-negative cervical intraepithelial neoplasia?Cancer Cytopathol. 2017 Oct;125(10):795-805. doi: 10.1002/cncy.21905. Epub 2017 Aug 17. Cancer Cytopathol. 2017. PMID: 28817235
-
Human Papillomavirus Detectability and Cervical Cancer Prognosis: A Systematic Review and Meta-analysis.Obstet Gynecol. 2023 Nov 1;142(5):1055-1067. doi: 10.1097/AOG.0000000000005370. Epub 2023 Sep 13. Obstet Gynecol. 2023. PMID: 37856917
References
-
- Massad LS, Einstein MH, Huh WK et al (2012) Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 17(5 Suppl 1):S1–S27. https://doi.org/10.1097/LGT.0b013e318287d329 - DOI
-
- Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH (1992) Interim guidelines for management of abnormal cervical cytology. JAMA 271(23):1866–1869 - DOI
-
- Perkins RB, Guido RS, Castle PE et al (2019) ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 24(2):102–131. https://doi.org/10.1097/LGT.0000000000000525 - DOI
-
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381. https://doi.org/10.1016/j.jbi.2008.08.010 - DOI - PubMed
-
- Harris PA, Taylor R, Minor BL et al (2019) The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 95:103208. https://doi.org/10.1016/j.jbi.2019.103208 - DOI - PubMed - PMC
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials